FDA Complete Response Letters (CRL) and Approval Precedent
Open the drug pipeline explorer’s FDA precedent view on a dated capture for rheumatoid arthritis: 71 US products whose label names the condition as a use (one more names it only to rule it out), each joined by application number to its original approval and to the complete response letters FDA has published. Six products have a letter on their original application dated before its approval. The letters come from openFDA’s export of 2 October 2026: 457 of its 458 records, leaving out one marked Under Review for Release.
Opens the drug pipeline explorer’s FDA precedent view on a reference capture for rheumatoid arthritis saved on 5 October 2026: ClinicalTrials.gov trials (the 100 most recent of 1,886) and the openFDA label search (label data as of 2 October 2026), joined to FDA files shipped with the suite: the CDER compilation of new molecular entities and new biologics, the breakthrough therapy lists, and the openFDA complete response letter export of 2 October 2026 (CC0). Label wording verdicts were re-checked on 17 October 2026 against the labels current that day. Nothing is fetched live. The capture expires on 4 December 2026.
What the join shows for rheumatoid arthritis
Each of the 71 products is joined by exact application number, never by name, to FDA’s CDER compilation, the breakthrough therapy lists, Drugs@FDA’s original approval date and the published letters. Sixteen join the compilation and so have a review time at original approval; their median is 290.5 days (n = 16).
Six have a published complete response letter on the original application, dated before its approval: TYENNE (tocilizumab-aazg), SIMLANDI (adalimumab-ryvk, two letters), YUFLYMA (adalimumab-aaty, two letters), TRUXIMA (rituximab-abbs), JYLAMVO (methotrexate oral solution) and SOVUNA (hydroxychloroquine sulfate). Across the eight letters, approval followed 181 to 545 days later. Each letter is shown as FDA published it, by application, company, date and type, with a link; nothing in it is summarised or explained.
Why the products with a letter have no review time
Four of the six are biosimilars licensed under section 351(k) of the Public Health Service Act; the other two are new formulations of drugs FDA had already approved. The compilation covers only new molecular entities and new biologics, so none of the six has a review time, and the median includes none of them.
Nor does a missing letter mean a clean review. FDA publishes only some letters, so a product without one here may still have received one; a review time includes any complete-response cycle, published or not.
Keep trial registry status apart from FDA action
A trial marked Completed on ClinicalTrials.gov has finished its protocol visits, not necessarily met its endpoint or led to approval. The registry records no application numbers or letters, so no trial is joined to a letter.
Equations and variables
Letter-to-approval interval
Δt = t_approval − t_letter (days)
- t_letter
- Date of a published complete response letter on the original application (no supplement)
- t_approval
- Original approval date of the same application in Drugs@FDA
Review time at original approval
T_review = t_approval − t_receipt (days)
- t_receipt
- Receipt date of the first complete application, from the CDER compilation
- t_approval
- Approval date in the compilation; computed only for products the compilation holds
Scope and limitations
- Complete response letters are those FDA has published; absence is not evidence that none was issued. Only letters on the original application dated before its approval are shown.
- The product list comes from each product’s current label; the original application, and any letter on it, may have been for another condition.
- The list follows the app’s label wording check, re-run on 17 October 2026. A product whose label names rheumatoid arthritis only to rule it out is left out (one here). The check reads wording, not intent: a label that rules the condition out in words the check does not know is still listed.
- Review time covers only CDER new molecular entities and new biologics approved to the end of 2025; biosimilars, new formulations and CBER products have none.
- Not medical, investment, legal or regulatory advice. These are FDA records as they stand; an interval or a median is historical, not a forecast for any product.
Sources and provenance
- ClinicalTrials.gov study records and APIClinicalTrials.gov terms; no new licence classification
Registry records are sponsor-submitted. Capture dates, search scope and NCT identifiers must accompany reuse.
- openFDA Complete Response Letters (transparency/crl)CC0; FDA source terms
Bulk export of 2 October 2026, retrieved 5 October 2026; 457 of 458 records kept, one marked Under Review for Release left out. Reduced to application, company, date, type and centre.
- Compilation of CDER new molecular entity and new biologic approvalsPublic domain (US government work)
Receipt and approval dates and designations; joined by exact application number.
- openFDA drug labels and Drugs@FDACC0; FDA source terms
Label search for rheumatoid arthritis saved 5 October 2026; label data as of 2 October 2026; wording verdicts re-checked 17 October 2026.
- FDA breakthrough therapy approvalsPublic domain (US government work)
CDER’s own lists.
Technical questions
If a product shows no letter here, was it approved on its first review cycle?
Not necessarily. FDA publishes only some complete response letters, so absence is not evidence that none was issued. Where the compilation gives a review time, it runs from receipt of the first complete application and includes any complete-response cycle, published or not.
Why does a biosimilar show a letter but no review time?
Review time needs the receipt date in FDA’s compilation of new molecular entities and new biologics. Biosimilars licensed under section 351(k) of the Public Health Service Act are not in it, so the view shows the letter and the days to approval, but no review time.
Does a Completed Phase 3 record on ClinicalTrials.gov mean the drug was approved by the FDA?
No. On ClinicalTrials.gov, "Completed" means participants are no longer being examined or treated under the protocol. Whether the trial met its endpoint, supported an NDA or BLA, preceded a complete response letter or led to approval is recorded elsewhere.
Connected workflows
- HER2 and TROP2 ADC trial-record exploration
Inspect the pinned six-record HER2 and TROP2 ADC clinical trial selection.
- US incretin listed-patent inspection
Examine FDA Orange Book application numbers, listed patents, and exclusivities.
- KRAS G12D trial-record exploration
Compare operational trial statuses across the KRAS G12D study landscape.